When was Lodo Therapeutics founded?

Lodo Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Lodo Therapeutics located?

Lodo Therapeutics is headquartered in New York City, United States. It is registered at Seattle, Washington.

How many employees does Lodo Therapeutics have?

As of Aug 31, 2026, the latest employee count at Lodo Therapeutics is 8.

Is Lodo Therapeutics a funded company?

Lodo Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jan 04, 2017.

When was the latest funding round of Lodo Therapeutics?

Lodo Therapeutics' latest funding was a $***** Series A round on Jan 04, 2017, with participation from 13 investors. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $881M in funding in 2026 to date.

Where does Lodo Therapeutics rank among its competitors?

Lodo Therapeutics ranks 11th amongst 117 active competitors, of which 30 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of Lodo Therapeutics?

Lodo Therapeutics' top competitors include Evofem, Insmed and Basilea. Among them, Basilea secured the most recent funding round in May, 2026.

Lodo Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer novel therapeutics to treat resistant infectious diseases and cancers using AI. The company is focused on the discovery, biosynthesis, and characterization of new, genetically encoded small molecules from microbial sources. The company's metagenomics-driven discovery platform is used for the identification of microbiome-based pharmaceutical products derived. It also offers products against tuberculosis.

Website: lodotherapeutics.com
Registered Address: Seattle, Washington

Key Metrics

Founded Year

2015

Location

New York City, United States

Stage

Acquired

Total Funding

$19.9M in 1 round

Latest Funding Round

Series A, Jan 04, 2017, $*****

Investors

AbbVie & 12 more

Ranked

11^th among 117 active competitors

Employee Count

8 as on Aug 31, 2026

Investment & Acquisitions

Hibiskus & 1 more

Similar Companies

Evofem & 150 more

Exit Details

Acquired by Zymergen (May 28, 2021)

View Lodo Therapeutics' full profile

Lodo Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LODO THERAPEUTICS CORPORATION CIN: 475538730 , United States, Active	Dec 26, 999	-	19 (As on Dec 31, 2020)	-

Lodo Therapeutics got acquired by Zymergen on May 28, 2021.

Click here to take a look at Lodo Therapeutics's acquisition in detail

Lodo Therapeutics has raised a total funding of $19.9M over 1 round. Its latest funding round was a Series A round on Jan 04, 2017 for $*****. 13 investors participated in its latest round. Lodo Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Lodo Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 04, 2017	9577717	Series A	3984842	4940942	8847787	8522549

Access funding benchmarks and valuations. Sign up today!

View details of Lodo Therapeutics's funding rounds and investors

The founders of Lodo Therapeutics is Sean Brady.

Here are the details of Lodo Therapeutics' key team members:

Sean Brady: Co-Founder of Lodo Therapeutics.

View details of Lodo Therapeutics's Founder profiles and Board Members

Lodo Therapeutics' employee count trend

Lodo Therapeutics has 8 employees as of Aug 26. Here is Lodo Therapeutics's employee count trend over the years:

Employee count trend for Lodo Therapeutics

Uncover Lodo Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lodo Therapeutics include Evofem, Insmed and Basilea. Here is the list of Top 10 competitors of Lodo Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	mercerstcap.com, Aditx Therapeutics & 10 others	66/100
2nd	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Foresite Capital, Quaker Partners Management ... & 13 others	66/100
3rd	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
4th	Centauri Therapeutics 2014, Kent (United Kingdom), Series A	Developer of immunotherapeutics to treat infectious diseases	$73M	Boehringer Ingelheim Venture Fund, REPAIR Impact Fund ... & 32 others	58/100
5th	SNIPR Biome 2011, Copenhagen (Denmark), Series B	Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely	$139M	Lundbeck Foundation, Life Sciences Partners ... & 7 others	57/100
6th	Eubiologics 2012, Seoul (South Korea), Public	Company providing customized services for development and manufacturing biologics from both mammalian cell and microbial-based systems.	$7.5M	IMM Investment, Global Health Investment Fund ... & 8 others	56/100
7th	Minervax 2010, Hellerup (Denmark), Series C	Developer of vaccines against life-threatening infections in newborns	$197M	EQT, Sanofi Ventures & 14 others	54/100
8th	Prokarium 2012, London (United Kingdom), Series C	Developer of bacterial immunotherapy treatments for various types of cancer	$70M	Korea Investment Holdings, Riyadh Valley Company ... & 9 others	52/100
9th	Aridis Pharma 2005, San Jose (United States), Public	Provider of human monoclonal antibodies against infectious diseases	$42.1M	Cystic Fibrosis Foundation, Lynx Financial ... & 5 others	51/100
10th	Affinivax 2013, Cambridge (United States), Acquired	Developer of technology-based conjugate vaccines against infectious diseases	$359M	Gates, Foresite Capital & 14 others	50/100
11th	Lodo Therapeutics 2015, New York City (United States), Acquired	Developer novel therapeutics to treat resistant infectious diseases and cancers using AI	$19.9M	AbbVie, Lilly & 11 others	48/100